• Subscribe
  • Magazine
  • Videos
  • Advertise
  • About Us
  • Smart Water Summit
  • Wastewater Summit
    • Recent Quotes
    My Watchlist
    Indicators
    WaterWorld Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Lava Therapeutics N.V. (NQ: LVTX )

    1.820 UNCHANGED
    Streaming Delayed Price Updated: 3:59 PM EST, Nov 5, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about Lava Therapeutics N.V.

    < Previous 1 2 3 Next >
    Why LAVA Therapeutics Stock Is Up More Than 100% Today
    LAVA Therapeutics N.V. 
    Via Benzinga
    LAVA Therapeutics Skyrockets After Cancer Agreement With Seagen
    Via Benzinga
    Seagen and LAVA Therapeutics Announce Exclusive Worldwide License Agreement to Advance LAVA-1223, a Preclinical Gamma Delta Bispecific T Cell Engager for EGFR-Expressing Solid Tumors
    From Seagen Inc.
    Via Business Wire
    5 Value Stocks To Watch In The Healthcare Sector
    The Meaning Behind Value Stocks A value stock is traditionally defined in terms of how investors in the marketplace are valuing that company's future growth prospects. Low P/E multiples are good base... 
    Via Benzinga
    Why Is It Moving? Looking At LAVA Therapeutics's Price Action Today
    LAVA Therapeutics's Stock Price And Volume Action LAVA Therapeutics's (NASDAQ: 
    Via Benzinga
    Benzinga's Top Ratings Upgrades, Downgrades For September 15, 2022
    Upgrades 
    Via Benzinga
    The Daily Biotech Pulse: Bristol Myers, BridgeBio Ink Oncology Pact, FDA Nod For Lava Therapeutics Blood Cancer Study And More
    Here's a roundup of top developments in the biotech space over the last 24 hours: 
    Via Benzinga
    Boeing, PriceSmart And 80 Biggest Movers From Yesterday
    Gainers Sharps Compliance Corp. (NASDAQ: SMED) shares jumped 196.1% to close at $8.44 on Tuesday after the company it will be acquired by an affiliate of Aurora Capital Partners for $8.75 per share. 
    Via Benzinga
    LAVA Therapeutics Highlights Encouraging Clinical Updates on Lead Cancer Program
    Via Benzinga
    LAVA Therapeutics Shares Interim LAVA-051 Data From Early-Stage Cancer Trial
    LAVA Therapeutics NV (NASDAQ: LVTX) announced initial data from its first clinical study with LAVA-051. The presentation will include data from the first... 
    Via Benzinga
    52 Biggest Movers From Yesterday
    Gainers BioDelivery Sciences International, Inc. (NASDAQ: BDSI) shares climbed 52.8% to close at $5.56 on Monday. Collegium Pharmaceutical will acquire BioDelivery Sciences... 
    Via Benzinga
    The Daily Biotech Pulse: ImmunityBio Reports Positive Readout, Valneva Starts Late-Stage Chikungunya Vaccine Study, Sio Gene Shelves Parkinson's Program
    Here's a roundup of top developments in the biotech space over the last 24 hours: 
    Via Benzinga
    40 Biggest Movers From Friday
    Gainers Nutriband Inc. (NASDAQ: NTRB) shares climbed 157.8% to close at $10.08 on Friday after the company announced the Korean Intellectual Property Office has fully issued its... 
    Via Benzinga
    The Daily Biotech Pulse: Moderna's Booster Shot Gets FDA Panel Backing, Decision Day For Avadel, Silence Therapeutics Strikes Licensing Deal, MiNK IPO
    Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Adcom Recommends Approval Of Moderna's COVID-19 Vaccine Booster Shot For... 
    Via Benzinga
    Exposures COVID-19 Product Safety
    35 Biggest Movers From Friday
    Gainers ChemoCentryx, Inc. (NASDAQ: CCXI) shares surged 96% to close at $38.41 on Friday. The FDA approved ChemoCentryx’s Tavneos (avacopan) as an adjunctive treatment for... 
    Via Benzinga
    Exposures Product Safety
    60 Biggest Movers From Friday
    Gainers IVERIC bio, Inc. (NASDAQ: ISEE) shares surged 62.5% to close at $14.12 on Friday after Apellis Pharmaceuticals reported results from its Phase 3 DERBY and OAKS studies in... 
    Via Benzinga
    21 Stocks Moving in Tuesday's Pre-Market Session
    Gainers Wilhelmina International, Inc. (NASDAQ: WHLM) shares rose 46% to $6.35 in pre-market trading following Form 4 filing from the company’s 10% owner, Retail Ecommerce... 
    Via Benzinga
    The Daily Biotech Pulse: Moderna's Vaccine Produces Durable Response Against Variants, FDA Approves Jazz's Sleep Disorder Drug, Dermata IPO
    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 12) Adagio Therapeutics, Inc. (... 
    Via Benzinga
    Exposures Product Safety
    88 Biggest Movers From Yesterday
    Gainers BeyondSpring Inc. (NASDAQ: BYSI) shares climbed 176% to close at $26.58 on Wednesday in reaction to topline data from DUBLIN-3 Phase 3 trial evaluating plinabulin in... 
    Via Benzinga
    75 Biggest Movers From Yesterday
    Gainers Arcturus Therapeutics Holdings Inc. (NASDAQ: ARCT) shares climbed 68.1% to close at $58.25 on Tuesday after the company announced that the it has received approval for a... 
    Via Benzinga
    40 Stocks Moving In Monday's Mid-Day Session
    Gainers Ever-Glory International Group, Inc. (NASDAQ: EVK) shares jumped 133% to $5.27 after the company announced a $5 million stock repurchase program. Exicure, Inc. (NASDAQ:... 
    Via Benzinga
    48 Stocks Moving In Tuesday's Mid-Day Session
    Gainers Wilhelmina International, Inc. (NASDAQ: WHLM) shares jumped 64.4% to $7.15 after a Form 4 filing from the company showed 10% shareholder Retail Ecommerce Ventures... 
    Via Benzinga
    21 Stocks Moving in Monday's Pre-Market Session
    Gainers Exicure, Inc. (NASDAQ: XCUR) shares rose 41.5% to $1.91 in pre-market trading. Ipsen and Exicure signed an exclusive collaboration agreement to research, develop, and... 
    Via Benzinga
    61 Biggest Movers From Yesterday
    Gainers Ever-Glory International Group, Inc. (NASDAQ: EVK) shares climbed 124.8% to close at $5.08 on Monday after the company announced a $5 million stock repurchase program.... 
    Via Benzinga
    48 Biggest Movers From Yesterday
    Gainers Welbilt, Inc. (NYSE: WBT) shares surged 44.5% to close at $22.58 on Wednesday after The Middleby Corporation announced plans to acquire the company. Skillz Inc. (NYSE:... 
    Via Benzinga
    75 Biggest Movers From Friday
    Gainers The New Home Company Inc. (NYSE: NWHM) jumped 82.9% to settle at $8.89 on Friday after the company agreed to be acquired by funds managed by affiliates of Apollo Global... 
    Via Benzinga
    The Week Ahead In Biotech: Johnson & Johnson, Biogen Earnings, Neurology Conference And IPOs
    The FDA and CDC announced their recommendation to pause the use of Johnson & Johnson's JNJ COVID-19 vaccine following incidences of severe clots. J&J's pain turned into gains for other COVID-19 vaccine... 
    Via Talk Markets
    Exposures COVID-19 Product Safety
    The Daily Biotech Pulse: Ardelyx Sinks On Regulatory Setback, AnPac Issues Positive Preannouncement, European Nod For Myovant, HCW Biologics Debuts On Wall Street
    Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 19) Cytokinetics, Incorporated... 
    Via Benzinga
    Benzinga's Top Ratings Upgrades, Downgrades For April 19, 2021
    Upgrades Compass Point upgraded the previous rating for Santander Consumer USA Holdings Inc (NYSE:SC) from Neutral to Buy. In the fourth quarter, Santander Consumer USA... 
    Via Benzinga
    The Week Ahead In Biotech: Johnson & Johnson, Biogen Earnings, Neurology Conference And IPOs
    Biotech stocks reversed course in the week ended April 16, with the sector rebounding along with the broader market. The week's news flow was fairly light. The American... 
    Via Benzinga
    < Previous 1 2 3 Next >
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.